Limitations, agreements, and source contact

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma · Source last updated 2025-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

ifmclinicaltrials@myelome.fr

organization

Intergroupe Francophone du Myélome

phone

+33 1 40 21 24 02

title

Chief Executive Officier

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice